(NO) is a an important signaling and effector molecule that plays critical roles in a remarkable array of essential biological processes, ranging from neurotransmission and the control of vascular tone to apoptosis and inflammation (26, 66). Through covalent modifications of target proteins and redox reactions with oxygen, superoxide radical, and transition metals, NO influences a number of biosynthetic, metabolic, and membrane transport processes important to normal renal function. Given the diverse actions of this molecule and the multiplicity of cell phenotypes with the explosion of new information about the molecular diversity and regulatory complexity of NO biosynthesis. At the current rate of over 4,000 publications per year on NO research, attempted encyclopedic reviews of the NO field will be incomplete and risk cursory analysis of the relevant data. Therefore this review explores selected, newly recognized developments in the biology and homeostatic functions of NO in the kidney and places particular emphasis on involvement of NO in the control of normal renal hemodynamics, the glomerular microcirculation, and renal salt excretion. in the kidney, it is not surprising that NO has become the darling of renal physiologists seeking to explain NITRIC OXIDE BIOSYNTHESIS complex, integrated functions of the kidney. For example, work to date has implicated NO in the paracrine Nitric Oxide Synthases control of basal renal and glomerular hemodynamics General structure and biochemistry. NO is metabo-(140, 161), the tubuloglomerular feedback (TGF) re-lized from L-arginine by NO synthases (NOW in a sponse (186, 208), and pressure natriuresis (55, 76). complex reaction requiring molecular oxygen, reducing Although promising advances in our understanding of equivalents from NADPH as cosubstrates, tetrahydrothe roles of NO in renal health and disease have been biopterin, a cytochrome P-450-type heme moiety, made, it has been difficult for investigators to keep pace calmodulin, and several tightly bound redox cofactors
Kone, Bruce C., and Chris Baylis. Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am. J. Physiol. 272 (Renal Physiol. 41): F561-F578, 1997.-Nitric oxide (NO) is an important molecular mediator of numerous physiological processes in virtually every organ. In the kidney, NO plays prominent roles in the homeostatic regulation of glomerular, vascular, and tubular function. Differential expression and regulation of the NO synthase (NOS) gene family contribute to this diversity of action. This review explores recent advances in the molecular and cell biology of the NOS isoforms and relates these findings to functions of NO in the control of normal renal hemodynamics, the glomerular microcirculation, and renal salt excretion. Newly recognized molecular diversity of the NOS gene products, factors governing NOS isozyme gene expression and catalytic activity, and the intrarenal distribution of the NOS isoforms are examined. Physiological data regarding the complex roles of NO in the control of renal hemodynamics and the glomerular microcirculation are analyzed, and the effects of chronic NOS inhibition on glomerular function and structure are presented. The contributions of NO to renal salt excretion as well as functional and molecular biological evidence for adaptive changes in NOS isoform expression during variations in dietary salt balance are discussed. Current investigative challenges and goals for future research of renal NO biology are presented. nitric oxide synthase; lus; renal vasculature salt balance; hypertension; shear stress; glomeru-NITRIC OXIDE (NO) is a an important signaling and effector molecule that plays critical roles in a remarkable array of essential biological processes, ranging from neurotransmission and the control of vascular tone to apoptosis and inflammation (26, 66) . Through covalent modifications of target proteins and redox reactions with oxygen, superoxide radical, and transition metals, NO influences a number of biosynthetic, metabolic, and membrane transport processes important to normal renal function. Given the diverse actions of this molecule and the multiplicity of cell phenotypes with the explosion of new information about the molecular diversity and regulatory complexity of NO biosynthesis. At the current rate of over 4,000 publications per year on NO research, attempted encyclopedic reviews of the NO field will be incomplete and risk cursory analysis of the relevant data. Therefore this review explores selected, newly recognized developments in the biology and homeostatic functions of NO in the kidney and places particular emphasis on involvement of NO in the control of normal renal hemodynamics, the glomerular microcirculation, and renal salt excretion. in the kidney, it is not surprising that NO has become the darling of renal physiologists seeking to explain NITRIC OXIDE BIOSYNTHESIS complex, integrated functions of the kidney. For example, work to date has implicated NO in the paracrine Nitric Oxide Synthases control of basal renal and glomerular hemodynamics General structure and biochemistry. NO is metabo-(140, 161), the tubuloglomerular feedback (TGF) re-lized from L-arginine by NO synthases (NOW in a sponse (186, 208) , and pressure natriuresis (55, 76) . complex reaction requiring molecular oxygen, reducing Although promising advances in our understanding of equivalents from NADPH as cosubstrates, tetrahydrothe roles of NO in renal health and disease have been biopterin, a cytochrome P-450-type heme moiety, made, it has been difficult for investigators to keep pace calmodulin, and several tightly bound redox cofactors (26) (Fig. 1) . The reaction can be inhibited to a variable degree by NG-substituted L-arginine analogs, such as NG-nitro-L-arginine methyl ester, as well as relatively NOS-isoform-selective inhibitors, such as 7-nitroindazole (for neuronal NOS) and aminoguanidine (for inducible NOS). To date, three broad categories of NOS isozymes, referred to in this review as neuronal (nNOS), endothelial (eNOS), and inducible NOS (INOS), have been purified and characterized from rodents and humans (Table 1 ). Although these isoforms have different molecular weights and variable cofactor requirements, all are NADPHand calmodulin-dependent and contain consensus binding sites for flavin adenine dinucleotide, flavin mononucleotide (FMN), tetrahydrobiopterin, and a heme complex (Fig. 2) . The two major "constitutive" NOS isozymes, nNOS and eNOS, exhibit strict dependency on intracellular Ca2+/calmodulin levels, produce "puffs" of NO for signaling purposes, and are expressed in a limited tissue distribution. Although they are classified as constitutive enzymes, expression of nNOS and eNOS is regulated by specific physiological and pathophysiological stimuli (see below). A novel 105kDa (native M,) protein with biochemical properties similar to nNOS was recently purified from rat cerebellum (36). This protein, termed nNOS-II, utilizes both L-arginine and the oligopeptide bradykinin as substrates in biochemical assays. The reaction it catalyzes is calmodulin-dependent with L-arginine, but calmodulin-independent with bradykinin as substrate. Moreover, with bradykinin as substrate, nNOS-II can be inhibited by both typical NOS inhibitors and specific B2-receptor antagonists. It remains to be established, however, whether this alternative pathway of NO production occurs in vivo. In addition, further work will be needed to determine the tissue distribution, primary structure, and biological relevance of the nNOS-II enzyme.
In contrast to these isozymes, iNOS, originally cloned from murine macrophage cell lines (211), is expressed in virtually all nucleated cells subjected to immunologic or certain nonimmunologic stimuli. Once expressed, iNOS remains tonically activated, although subject to feedback inhibition (2), producing large amounts of NO for cytoactive purposes. Although its activity was originally believed to be Ca2+/calmodulin independent, owing to its tight binding of calmodulin, recent studies with purified, recombinant iNOS protein indicate that iNOS is twice as active in the presence of Ca2+ as in its absence (198) . Therefore, the common practice of measuring L- [3H] arginine to L-[3H] citrulline conversion in the presence and absence of Ca2+ to distinguish iNOS from nNOS and eNOS may yield erroneous estimates of the contributions of these isozymes to overall NOS activity. Similarly, although initially thought to be a soluble enzyme, iNOS has been shown to be associated with 50-to 80-nm vesicles in primary mouse macrophages (202). The ability to associate with membranes of vesicular iNOS is apparently the result of a yet to be characterized posttranslational modification that increases the mass of the protein by 4.5 kDa (202). Finally, the paradigm that iNOS requires a provocative immune stimulus for induction has been challenged by the observation that iNOS is expressed in several normal adult and fetal tissues (30, 54, 68, 128, 151, 164, 206, 216) , including the adult and fetal kidney (1, 17, 131, 133) . Indeed, the first 3.8 kb upstream of the transcription initiation site of the human iNOS gene exhibited basal promoter activity when expressed by transfection in a human liver epithelial cell line (47). lMoZecuZar diversity.
The encoding DNAs and genes for the major NOS isozymes have been cloned and characterized (Table l) with different 5'-terminal exons joined to a common second exon (210). Transcripts bearing deletions of exons 9 and 10 and exon 10 have also been reported (57, 71), but it is unknown whether these mRNAs generate functional proteins in vivo or whether they are expressed in kidney. An alternative splice variant, termed nNOS-u, was recently identified in rat (116, 177) . This variant contains a 34-amino-acid segment transcribed from intron 16 (Fig. 2) , exhibits similar catalytic activity to that of cerebellar nNOS, but differs in its tissue distribution from nNOS. Transcripts encoding this variant were detected in differentiated skeletal muscle, heart, penis, urethra, prostate, pelvic plexus, bladder, and cerebellum (116, 177), but its renal expression has not been explored in detail. As discussed above, nNOS-II has been purified and biochemically characterized, but its primary structure has not been determined (33). nNOS knockout mice (Table  1) exhibit hypertrophy of the pyloric sphincter, resistance to ischemic insults to the brain, and increased aggressive behavior (male mice) but otherwise show no gross anatomic or functional abnormalities (79, 141). Several laboratories have now embarked on detailed studies of the renal physiology of these mutant mice.
Highly homologous eNOS cDNAs were first cloned from bovine (172) and human (94) endothelial cells, and we have characterized a partial eNOS cDNA cloned from rat kidney (130). The primary structure of fulllength eNOS lacks the NH2-terminal 230 amino acids present in nNOS (Fig. 2) IFN-v-activated charide (LPS) and cytokines suggests that they may have important biological roles. The complete rodent iNOS genes have not yet been cloned, but -4 kb of the 5' control region for the mouse iNOS gene (207) and -1.6 kb of the 5'-flanking region of the rat VSM-NOS gene have been characterized (50). The rodent and human genes contain a TATA box and numerous consensus binding elements for transcription factors involved in bacterial LPS, hypoxia, CAMP, or cytokine inducibility of other genes (Fig. 3) . However, there are major differences in sequence and potential cis-acting elements in the 5'-promoter regulatory regions cloned from rodents and humans (as detailed below); whereas only -1 kb of the proximal 5'-flanking region of the murine iNOS gene was necessary to confer inducibility to LPS and interferon (IFN)-y (113, 213), cytokine-responsive elements of the human iNOS 5'-flanking region were distributed over at least 16 kb (47). In addition, the human iNOS gene, but not the rodent counterparts, contains a shear-stress responsive element (GAGACC) that merits further investigation (146). iNOS knockout mice (Table 1 ) exhibit increased . susceptibility to intracellular pathogens and tumors and a blunted hypotensive response to bacterial LPS (115). Again, results from studies of the renal function of these animals have not been reported.
Intrarenal Distribution of NOS Isoforms
Biochemical studies have shown that the renal medulla has a greater capacity to generate NO than the renal cortex. For example, McKee et al. (126) observed that the renal medulla basally expresses considerable NOS activity (-20% of the highly NOS-enriched cerebellum) and that the basal medullary NOS activity is threefold greater than that of renal cortex. NADPHdependent diaphorase activity, a histochemical index of catalytic NOS activity, has also been used to determine renal cell types likely to express NOS isozymes. Two groups reported strong NADPH-dependent diaphorase activity in the rat macula densa segment (MDS) (208), and McKee et al. (126) reported that the medullary thick ascending limb (MTAL) exhibited the greatest NADPH-depen .den t diaphorase staining of any ron segment in the rat.
Several laboratories have used immunohi stochemistry or in situ hybridization with NOS isoform-specific antibodies or nucleic acid probes to localize the major NOS isoforms within the kidney ( Table 2) . As alluded to above, however, renal functional and localization studies of the recently discovered nNOS and iNOS alternative forms have not been reported, and the specificity of the various reagents used to localize the NOS isoforms in earlier reports must now be reexamined.
Colocalization of nNOS transcripts and immunoreactivity in the MDS have been demonstrated in several mammalian species (7), and nNOS immunoreactivity has been shown in the MDS in humans (7); thus there is general agreement that the MDS is the principal site of nNOS gene expression in the rat kidney (7, 178, 208 cortical and outer medullary collecting duct, and renal vasculature. Since these structures exhibited neither nNOS immunoreactivity nor significant NADPH-dependent diaphorase staining, the amount of nNOS mRNA detected by RT-PCR in these segments may not be physiologically meaningful or may reflect expression of an alternative nNOS form not detected by available antibodies.
eNOS mRNA and protein have been reported in renal cortex and medulla of the rat (Table 2) . Using RT-PCR of microdissected renal structure, Ujiie et al. (195) detected eNOS mRNA in glomeruli, preglomerular vasculature, proximal tubules, thick ascending limbs (TAL), and collecting ducts. Immunohistochemical studies localized eNOS protein expression principally to the endothelium of the glomerular capillaries, the afferent and efferent arteriole, the intrarenal arteries, and the medullary vasa recta (7).
iNOS mRNA expression has been identified in the kidneys of normal rats (Table 2 ). Using competitive RT-PCR combined with diagnostic restriction endonuclease digestion, we demonstrated that the MAC-NOS isoform was expressed basally in several renal tubule segments, with highest expression in the MTAL, whereas the VSM-NOS isoform was principally expressed in the glomeruli and interlobular and arcuate arteries of the normal rat kidney (131). Morrissey et al. (133) independently reported abundant iNOS mRNA in the MTAL of the normal rat. Since previous in situ hybridization and immunohistochemical studies of nNOS and eNOS expression (7) failed to detect mRNA or protein for these isozymes in the MTAL, and since the MTAL is the tubule segment expressing the most abundant iNOS mRNA, it is logical to conclude that the abundant NADPH-diaphorase activity present in the MTAL (126) represents constitutively functional MAC-NOS. In situ hybridization studies of normal rat kidney with a riboprobe common to MAC-and VSM-NOS revealed signal in the S3 segment of the proximal tubule, the cortical and medullary TAL, the distal convoluted tubule, and the cortical collecting duct and IMCD of the normal rat (1). In contrast to earlier immunohistochemical studies (167, 168) , no significant iNOS labeling was observed in the afferent arteriole. These results indicated that iNOS mRNA is tonically and differentially expressed along the normal rat nephron, with highest abundance in the MTAL.
The localization of iNOS immunoreactivity in the kidney has been more problematic. Conflicting results have been reported with different anti-iNOS antibodies. The afferent arteriole of the normal rat was labeled with one anti-iNOS antibody (188, 189), intercalated cells of the normal collecting duct with another antibody (187), and glomeruli in a rat model of immune . complex glome&lonephritis with a third anti-iNOS antibody (93). Although the discrepancies among these data and between these results and the mRNAlocalization studies may reflect the inability of the available antibodies to detect both rat iNOS isoforms, further studies will be needed to reach a consensus on the intrarenal distribution of iNOS protein.
Regulation of NO Biosynthesis
With the exception of nNOS-II, which employs bradykinin as substrate (33) These data have been detailed in several recent reviews (23, 72, 101, 139) . Below, we highlight recently described regulatory mechanisms that remain to be explored in the kidney. nNOS. The expression of nNOS is developmentally regulated in brain (144) and lung (143), and pulmonary expression of nNOS mRNA and protein is enhanced after prolonged in vivo hypoxia (173). These findings suggest that this gene can be transcriptionally controlled. The nNOS 5'-flanking region contains a TATA box, CAAT box, and consensus binding sites for AP-2, CREB/activating transcription factor, NF-KB, nuclear respiratory factor 1, and other potential factors, but involvement of these or other transcription factors in the control of nNOS gene expression has not been established. The recent reports that changes in dietary salt intake produce inverse variations in nNOS gene expression selectively in macula densa cells (21, 178) invite detailed studies of nNOS transcriptional control in this setting. Moreover, transgenic animal methodology should be useful in determining the cis-elements governing the renal cell-type-specific expression of this gene.
In vitro studies have demonstrated that nNOS catalytic activity is regulated by the phosphorylation state of the enzyme. Whether this mode of nNOS regulation occurs in vivo remains to be convincingly established. In vitro phosphorylation of nNOS by protein kinase A, protein kinase G, protein kinase C, or Ca2+/calmodulindependent protein kinase reduces catalytic activity (24, 42, 48, 136) , whereas calcineurin-mediated dephosphorylation of the enzyme enhances catalytic activity (42). In addition, in vitro phosphorylation studies of wild-type and NH2-terminal deletion mutants of nNOS indicate that the wild-type enzyme autophosphorylates, presumably at S I71 (204). Although functional activity was not assessed in these studies, the nNOSspecific autophosphorylation pathway might regulate enzyme activity (204).
Although originally believed to be a cytosolic enzyme, nNOS has been found associated with integral membrane and cytoskeletal proteins of the skeletal muscle sarcolemma (28) and with the rough endoplasmic reticulum in neurons (74). The NH2 terminus of nNOS contains a PDZ domain (also known as GLGF-repeat) that binds q-syntrophin (28), a dystrophin-associated protein, and two postsynaptic density proteins, . PDZ domains mediate protein-protein interactions that have been implicated in clustering of signaling and receptor molecules and the coupling of receptors to effector enzymes (73). Since proteins bearing PDZ domains typically localize to specialized cellcell contacts (23) and the juxtaglomerular apparatus comprises different cellular interfaces, it will be interesting to determine whether nNOS is spatially distributed within the MDS and whether such geometry is important to MDS function. Similarly, the recent characterization of a highly conserved lo-kDa peptide, named PIN, which is widely distributed among tissues and binds to and inhibits the activity of nNOS, introduces another level of complexity to the regulation of this isozyme for consideration (91). Detailed studies of PIN expression and regulation in the kidney, particularly in the MDS, are clearly needed.
eNOS. Virtually nothing is known about the molecular mechanisms controlling eNOS expression in renal vascular or glomerular endothelium, so inferences drawn from other tissues and systems should be helpful in guiding future research in the kidney. In vivo data indicate that eNOS gene expression can be modulated by chronic hypoxia (173), chronic exercise (171), and during fetal development (143, 144) . Endothelial cell culture studies suggest that shear stress (92, 162), oxygen tension (5), transforming growth factor-l31 (85), protein kinase C (147), tumor necrosis factor-a (218), lysophosphatidylcholine (220), and the degree of cellular proliferation (4) all influence the level of eNOS gene expression via changes in gene transcription rates and/or mRNA stability. Structure-function analysis of the eNOS promoter/enhancer region has provided evidence for cis-elements involved in the control of eNOS gene transcription.
The Spl element appears to be necessary for basal eNOS gene transcription in endothelial cells, and GATA-2 binding, synergistically with Spl factors, appears to modulate the level of eNOS gene expression (221). NF-1 binding to a putative transforming growth factor-p1 promoter response element is important for transforming growth factor-p1 transactivation of the bovine eNOS gene (85). Additional structure-function studies of the eNOS gene are being pursued in several laboratories.
eNOS undergoes several posttranslational modifications, including phosphorylation, N-myristoylation, and cysteine palmitoylation, that regulate both activity and subcellular localization of the enzyme. Studies in culture bovine aortic endothelial cells demonstrated that eNOS can be tyrosine phosphorylated, a response that is enhanced by exposure of the cells to hydrogen peroxide or protein tyrosine phosphatase inhibitors. Moreover, the increased tyrosine phosphorylation of eNOS prompted by these maneuvers was associated with a substantial decrease in eNOS-specific activity (60). Other studies in bovine aortic endothelial cells revealed that bradykinin tyrosine phosphorylates a 90-kDa protein, eNOS-associated protein 1 (ENAP-l), that specifically interacts with eNOS and promotes association of eNOS with the membrane cytoskeleton (199). Conceivably, tyrosine phosphorylation-dependent interaction of eNOS with the cytoskeleton might direct NO production to specific subcellular locations. (103, 132, 135, 139, 150, 183) . This regulatory complexity presumably reflects the necessity for cell-type-specific control of this ubiquitous enzyme. For example, our studies in murine MTAL cells indicate that NF-KB p5O/p65 proteins, but not c-Rel, are involved in LPS inducibility of the iNOS gene (103), where as NF-KB p50-c-Rel mediates this response in murine macrophages (212). Similarly, the mechanism by which NF-KB activates the iNOS promoter in vascular smooth muscle cells in response to cytokines appears to be markedly different from that which confers LPS inducibility in macrophages (180).
Detailed analyses of the highly complex 5' gene control region of the iNOS gene has been undertaken in several laboratories (Fig. 3) . Mutational analysis of the murine iNOS 5'-flanking region fused to reporter genes and transfected into RAW 264. elements that mediate the inductive effects of LPS, whereas the synergistic effects of IFN-y are restricted only to region ZZ. The action of LPS in these cells is dependent on NF-KB heterodimers (p50-c-Rel) binding to the downstream iNOS NF-KB sequence (nucleotides -85 to -75; Ref. 212), whereas the synergistic effect of IFN-y to activate iNOS transcription requires inclusion of the distal half of the promoter and, at a minimum, binding of interferon regulatory factor-l (IRF-1) to its cognate sequence (-923 to -913) in the promoter/ enhancer (113, 121, 212, 213) . Region Z appears to serve as a core promoter module (3), whereas the region from -1588 to -722 functioned in an orientationand position-independent manner, suggesting that it serves as a classic enhancer element (3). Substitution of heterologous DNA between the two regions did not alter maximal promoter activity, suggesting that no other regulatory elements reside in the intervening region (-722 to -209) . In vivo footprinting verified protein occupation of both NF-KB sites, an IRF-I site, NF-IL6 [homologous to CCAAT/enhancer binding protein (CYEBP)] sites, and several other sites that do not correspond to known consensus sequences (63). Indeed, our preliminary work suggests that C/EBP-P transactivates the iNOS gene in LPS-treated MTAL cells (69). A cytokine-responsive element (-890 to -1002) and a hypoxia-responsive enhancer element (HRE; -227 to -229), bearing close homology to the erythropoietin-responsive enhancer element (ERE), have also been identified in the murine iNOS promoter; the latter appears to account for hypoxia inducibility of iNOS gene transcription in ANA-l macrophages (129). Silencing mechanisms have been implicated in iNOS transcriptional control as well. A full-length iNOS promoter construct bearing mutation of the -913 to -923 IRF-1 element yielded greater LPS-induced expression of reporter gene activity than did the wild-type promoter, indicating that this element may also function as a silencer (121). Since this mutation also rendered IFN-y suppressive, rather than stimulatory, an IFN-y-activated silencing mechanism must also be operative outside the IRF-1 element. However, the hazards of extending conclusions drawn from these in vitro studies to the in vivo setting are highlighted by the fact that a single NF-KB site was sufficient for LPS induction of iNOS promoterreporter gene constructs transfected into MW 264.7 cells (as detailed above), yet knockout mice lacking genes encoding IFN-7 (41), IRF-1 (98), or an IFN-)I receptor subunit (81) exhibited little or no LPS induction of iNOS. Thus the IFN-7 signaling pathway appears to be critical for LPS induction of murine iNOS in vivo.
Analysis of the human iNOS promoter revealed marked differences from murine iNOS in its transcriptional regulation. In contrast to murine iNOS, the first 3.8 kb upstream of the human iNOS gene demonstrated basal promoter activity but was unresponsive to LPS and cytokines. However, three cytokine-responsive regions in the human iNOS gene were identified at sites (-3.8 to -5.8, -5.8 to -7.0, and -7.0 to -16.0 kb) remote from the core promoter module (47). Structure-function studies revealed that the proximal region of the human iNOS promoter contains several inactivating nucleotide substitutions compared with the corresponding (LPS-responsive) region of the mouse iNOS gene (222). These structural differences, coupled with the apparent lack of LPS-inducible NF-KB/ Rel complexes in human macrophages, appear to contribute to the inability of LPS, with or without IFN-y, to activate strongly iNOS gene transcription in human monocytes and macrophages (222).
In contrast to the wealth of data concerning control of iNOS induction in pathological states, little is known about homeostatic regulation of iNOS expression in tissues, like the kidney, that constitutively express this enzyme. Presumably, iNOS expression in these settings results from basal autocrine or paracrine production of cytokines, growth factors, or hormones. The fact that iNOS expression is developmentally modulated in several tissues (17, 30, 216) , hormonally regulated in the female reproductive tract (78), and varies in the renal medulla with changes in salt balance (124) indicates that nonimmune regulation of iNOS contributes to the normal function of several organs. Transforming growth factor-p1 appears to be one factor that negatively modulates renal iNOS expression in vivo; transforming growth factor-p1 knockout mice exhibit enhanced iNOS expression in kidney and heart (201). Thus local control exerted by this growth factor may be one mechanism for cell-type-specific expression of iNOS in the kidney. Tyrosine kinases and phosphatases appear to be involved in posttranslational modification of iNOS, and may potentially play a role in modulating the functional activity of the enzyme (150). Since shear stress activates tyrosine kinases in endothelial cells (6, 39) and the 5' control region of the human iNOS gene contains a shear-stress response element (146), it will be interesting to determine whether shear stress activates iNOS activity or expression in the macro-and microvascular endothelial cells of the kidney.
Since basal iNOS gene expression is highest in the MTAL and IMCD (126, 131, 133) , segments that normally function in a relatively hypoxic environment (29, loo), the recent discovery that iNOS is an hypoxiainducible gene (108, 129) provides at least one mechanism that may account for constitutive expression of iNOS in these segments. It is tempting to speculate that "constitutive" iNOS expression in the MTAL and IMCD relates to tonic activation of factors that bind the iNOS-HRE and trans-activate the iNOS gene. Such a construct would predict that iNOS expression would vary directly with oxygen utilization and the demand for active transport in these nephron segments. Indeed, iNOS protein levels were 50% greater in the inner medulla of rats chronically adapted to a high-salt diet compared with rats on a low-salt diet (124). More detailed mechanistic studies, currently underway in our laboratory, should clarify this position. some of the increase in RVR is autoregulatory; however, intrarenal local and low-dose SY stemic NOS inhibition produces renal vasoconstricti .on in the absence of increased BP (65, 161, 209) . Thus NO tonically generated within the kidney lowers RVR. Increases in RVR due to NO synthesis inhibition cause reductions in renal plasma flow (RPF) and glomerular filtration rate (GFR), although GFR decreases proportionately less than RPF because filtration fraction rises (161).
These vasoconstrictor effects persist for the duration of NO synthesis inhibition, even in the conscious animal where all buffer mechanisms are operating. This result suggests that NO is not part of the feedback control of BP and vascular tone but rather sets the level of tone at which the other control systems operate. There is, however, no consensus as to how much of the vasoconstriction due to NOS inhibition results from withdrawal of an active NO vasodilatory stimulus and how much is secondary to amplification of underlying vasoconstrictor systems. The variability in the literature probably reflects differences in experimental preparations. It is likely that the role of vasoconstrictor systems in mediating the responses to NO synthesis inhibition is less important in the unstressed, conscious preparation than in surgically stressed, anesthetized animals.
The response to systemic NOS inhibition closely resembles the response to ANG II infusion, suggesting that ANG II participates in NOS inhibition-induced vasoconstriction (161). When the ANG II system is acutely activated (by volume depletion, surgical stress, etc.), or when exogenous ANG II levels are raised by infusion, the renal vasoconstrictor response to acute NOS inhibition is partly due to ANG II (12, 161, 176, 190) . In the conscious, unstressed rat, however, endogenous levels of ANG II are low, and are not tonically controlling renal hemodynamics. In this preparation, blockade of the endogenous ANG II system has little or no effect on NOS inhibition-induced renal vasoconstriction (10, 161, 176) . Because of these observations, we previously concluded that ANG II is not inevitably involved in the vasoconstrictor responses to NOS inhibition. However, this position has now been modified (see below).
There is also controversy about the role of the sympathetic nervous system (SNS) in the vasoconstrictor responses to acute NOS inhibition. Some workers report that SNS inhibition (ganglion blockade, pithing, or adrenergic receptor inhibition) has little effect on the increase in BP and RVR seen with acute NOS inhibition (161). In contrast, others claim that the hypertension and renal vasoconstriction are partly due to central and peripheral sympathetic activation (31, 105, 161, 193) . Again, the experimental preparation, and thus level of activation of the SNS, may be a key factor in determining the contribution of the SNS. In the conscious, chronically catheterized rat, where efferent renal sympathetic nerve activity is low, renal denervation has no impact on the renal hemodynamic responses to either NOS inhibition or NOS stimulation with L-arginine (22). This suggests that neither direct nitrergic innervation (149) nor attenuation of renal efferent sympathetic nerve activity is involved in maintenance of renal perfusion by NO. We recently observed that in the conscious rat, acute systemic a-adrenoceptor blockade does not attenuate either pressor or renal vasoconstrictor responses to acute NOS inhibition. The obvious interpretation, that the SNS is not involved in expression of the vasoconstrictor effects of NOS inhibition, proved to be incorrect. Although inhibition ofANG II or the SNS alone has little impact on the pressor response to acute NOS inhibition in the conscious rat, combined ANG II and SNS inhibition attenuates the rise in BP while leaving the renal vasoconstriction intact (161, 169) . The mechanism of the interaction between ANG II and the SNS is not clear but may involve actions of NO in the brain to inhibit central sympathetic outflow (31, 193) . Thus even in the unstressed state, both ANG II and the SNS are important mediators of the pressor response to acute NOS inhibition, via a complex interaction with the SNS. The findings in normal rats with acute NOS inhibition are remarkably similar to those we reported earlier in the rat with chronic NOS inhibition (169), despite the significant vascular and renal pathology that had also developed with long-term NOS blockade.
Of importance, there is a dissociation between the pressor and renal vascular responses to NOS inhibition, in terms of interactions withANG II and the SNS. Differences in NO-dependent regulation of tone in kidney versus peripheral blood vessels were also observed by us in other contexts (12, 13, X9), suggesting that there are fundamental differences in the way NO regulates vascular tone in the kidney compared with other organs. Perhaps NO lowers systemic vascular resistance and thus BP largely by antagonizing vasoconstrictor tone, whereas locally generated endothelial NO tonically relaxes the renal vasculature.
Endothelin (ET) is a potent vasoconstrictor peptide with widely distributed receptors throughout the peripheral and renal vasculature (61, 205) . Acute systemic NOS inhibition potentiates the vasoconstrictor actions of ET and also enhances the synthesis and release of ET (104). Ther e are both ETA and ETB receptors in the kidney, although there is controversy about the physiological role of these ET receptors in regulation of peripheral and renal vascular tone (61, 205) . In the normal, conscious rat we found that the pressor response to acute NOS inhibition was attenuated by concomitant inhibition of ET (158 the renal vasoconstriction was also seen but only as a secondary response to the blunted pressor effect (158).
Overall, withdrawal of NO amplifies any vasoconstrictor systems that are currently active. In the basal, relaxed state, when tonic vasoconstrictor tone is low, marked renal vasoconstrictor responses to acute NOS inhibition persist, even after attenuation of the pressor response, with combined ANG WSNS blockade. These data suggest that, tonically, NO exerts a direct vasodilatory effect on the renal microcirculation, possibly via eNOS, whereas the action of NO on the general circulation is more complex, involving attenuation of the activity ofANG II/SNS with a small ET contribution.
NO and Glomerular Microcirculation
In vivo glomerular micropuncture studies have shown that during systemic NOS inhibition, when BP rises, marked increases occur in both preglomerular (&) and efferent arteriolar (RE) resistances (Fig. 4) (43, 140, 161, 219) . As a result, glomerular plasma flow falls, but single-nephron GFR is maintained, because of the large rise in glomerular blood pressure (Pot) resulting from the increased BP and RE. In addition, the glomerular capillary ultrafiltration coefficient (&) is reduced (43, 219), probably mediated by mesangial cell contraction, since in vitro NO relaxes the glomerular mesangial cell (161). As discussed above, systemic NOS inhibition produces widespread vasoconstriction leading to a pressor response that produces an autoregulatory rise in RVR separate from the direct, local effects of intrarenal NOS inhibition (140, 161). Accordingly, local intrarenal inhibition of NO generation causes smaller increases in RVR than are seen during systemic NOS inhibition (43, 65). As shown in Fig. 4 , local intrarenal NOS inhibition in the cortical glomerular microcirculation increases RA but has no effect on RE. A similar &reducing effect is seen with both local and systemic NOS inhibition, suggesting equivalent levels of intrarenal NOS inhibition (43). In vitro studies on isolated microperfused cortical arterioles from rabbits also suggest that local generation of NO plays a greater role in control of RA than RE in cortical vessels (51,87,88>. In contrast, local NOS inhibition increases both RA and RE of the in vitro Fig. 4 juxtamedullary nephron preparation (140, 161), sug--gesting that tonically produced NO controls both R A and RE i n deep glomeruli. The cortical efferent arteri .ole is certainly capable of making and responding to NO when exposed to agonists, high shear rates, and in the hydronephrotic kidney (9, 58, 75), and NOS is present in abundance in the efferent arteriole (7). Whv NO is not tonically released in the cortical efferent arterioles under normal conditions, not clear, but it may be even part when NOS is present, is of the complex system allowing independent control over tone in RA and RE (87, 140, 161 ) and thus exquisite control over glomerular hemodynamics.
What causes the increased systemic NO inhibition when blood pressure RE with rises is also unknown, since inhibition of locally generated NO is not responsible. Presumably, some secondary vasoconstrictor systems are activated, and we have preliminary data suggesting that both ANG II and ET may be involved (160) (see below).
In must vivo studies on the glomerular microcirc be conducted under general anesthesia, ulation which inevitably activates pressor systems. Anumber of micropuncture studies have implicated ANG II and the SNS in the glomerular microcirculatory changes seen with systemic NOS inhibition (59, 140, 161, 185, 196) .
There is, however, little agreement on the exact locations at In vitro suggest which and in NO interacts with these pressor systems. vivo studies in cortical vessels in the rat that ANG II exerts predominantly vasoconstrictor actions during NOS --efferent arteriolar inhibition (46, 53), whereas in the rabbit isolated arterioles and in vivo in dogs, NO and ANG II interact primarily at the afferent site (87, 88, 170) . In the rat juxtamedullary glomeruli and as recently observed by us in the cortical microcirculation, NO and ANG II are shown to interact at both afferent and efferent arterioles (148,160). In the case of the SNS, renal nerve activity appears to play a small role in NOS inhibitor-induced increases in vivo in both RA and RE in the rat cortical microcirculation (59), although in rabbit isolated afferent arterioles, NOS inhibition does not amplify the vasoconstriction produced by applied norepinephrine (88). ET-induced constriction of the isolated rabbit afferent arteriole is blunted by tonically produced NO (89). In the hydronephrotic rat kidney, ET and NO also interact in control of afferent but not efferent arteriolar tone (67). In in vivo studies in normal rat, ET mediates some of the increased tone in both afferent and efferent vessels following NOS inhibition (160). In fact, the combined actions of ANG II and ET appear to be responsible for the increased RE seen with acute, pressor doses of NOS inhibitors (160 (186, 208) . Vallon and Thomson (197) agree that NO attenuates the TGFinduced increase in RA but argue that this is not mediated via macula densa signaling. In vitro studies suggest that NO blunts the TGF-induced increase in RA only when the macula densa is perfused with high NaCl (90). NO may also influence the myogenic component of autoregulation, but while there is a suggestion that NO contributes to low-pressure dilation of RA, renal autoregulatory ability is relatively intact during NO inhibition, although RVR is reset to a higher value (140,161).
Effects of Long-Term NOS Inhibition
It is possible to produce a sustained hypertension by chronic administration of NOS inhibitors.
In the absence of severe pathology, the glomerular hemodynamic responses to chronic, partial NOS inhibition for 8 wk are remarkably similar to those seen with acute systemic NOS inhibition (43, 161) : that is, systemic hypertension, renal vasoconstriction involving both afferent and efferent resistance vessels, and reductions in Kf (14) . Because of the systemic hypertension and increase in RE, P oc is chronically elevated, and these rats display moderate proteinuria and histological evidence of structural damage with a mild increase in focal and segmental glomerular sclerosis (14). More complete NOS inhibition leads to severe hypertension and further elevations in P oc, which probably contributes to the increased glomerular injury in the more severe models (14, 16, 161) .
In addition to glomerular hypertension, NO deficiency can lead to mesangial cell expansion and overproduction of extracellular matrix, which also predisposes to glomerular injury (49 
NO in Regulation of Salt Balance
As discussed above, eNOS, nNOS, and iNOS isoforms are all constitutively expressed in various locations throughout the tubule epithelium. There is strong in vitro evidence that NO has direct tubular actions to inhibit sodium reabsorption in proximal tubules and collecting duct by inhibition of Na+/H+ exchange, Na+-K+-adenosinetriphosphatase (Na+-K+-ATPase), and amiloride-sensitive Na+ channels (37, 102, 114, 126, 167, 181, 182) . Our recent studies in an iNOStransfected MTAL cell line (102) indicate that constitutive NO expression limits Na+-K+-ATPase al-subunit gene expression and Na+-K+-ATPase activity, the principal driving forces for Na+ reabsorption, consistent with a role for NO in facilitating Na+ excretion (Fig. 5) . NO is also important in mediating pressure natriuresis (118,168), probably via control of medullary blood flow and renal interstitial hydrostatic pressure (55, 70, 125) . In apparent conflict with these studies, where NOS inhibition prevents or attenuates the pressure natriuresis (118, 168), earlier work by us and others demonstrated a marked natriuretic response in the rat during systemic NOS inhibition (11, 95) . Since this was accompanied by an abrupt rise in BP, we interpreted this as a pressure natriuresis. Recent observations, however, suggest that the natriuresis seen with acute, systemic NOS inhibition can be dissociated from the rise in BP and is somehow related to the activity of the renal nerves (22, 169) .
There is also some evidence that increased dietary salt intake in normal animals promotes NO synthesis, A low dose of NOS inhibition produces a vasoconstrictor response that is confined to the kidney (15, 203). These low doses produce no pressor effect in rats or dogs on normal salt diet, but elevations in BP do occur with high salt intake by a volume-dependent effect (106, 217 
